Stock Track | Supernus Pharmaceuticals Plunges 12.28% After-Hours Despite Beating Q3 Estimates, Reports Operating Loss

Stock Track11-05

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) tumbled 12.28% in after-hours trading on Tuesday, despite the company reporting better-than-expected third-quarter results. The sharp decline reflects investor concerns over the company's profitability and modest revenue growth.

Supernus reported a quarterly loss of $0.80 per share, which, while beating analyst estimates of a $1.10 loss, represents a significant downturn from the $0.69 earnings per share reported in the same period last year. This 215.94% decrease in earnings appears to have rattled investors. Additionally, the company posted an operating loss of $60.231 million for the quarter, further fueling concerns about its financial performance.

On a more positive note, Supernus reported quarterly sales of $192.103 million, surpassing analyst expectations of $180.523 million by 6.41%. However, this represents only a 9.34% increase from the $175.689 million reported in the same quarter last year, which may have been viewed as insufficient growth by some investors. The company also provided guidance for full-year revenue between $685-705 million and adjusted operating earnings of $125-145 million, which may have fallen short of market expectations, contributing to the stock's after-hours plunge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178412502?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 05:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178412502","market":"us","top_or_hot":-1,"title":"Stock Track | Supernus Pharmaceuticals Plunges 12.28% After-Hours Despite Beating Q3 Estimates, Reports Operating Loss","media":"Stock Track","content":"<p>Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) tumbled 12.28% in after-hours trading on Tuesday, despite the company reporting better-than-expected third-quarter results. The sharp decline reflects investor concerns over the company's profitability and modest revenue growth.</p>\n\n<p>Supernus reported a quarterly loss of $0.80 per share, which, while beating analyst estimates of a $1.10 loss, represents a significant downturn from the $0.69 earnings per share reported in the same period last year. This 215.94% decrease in earnings appears to have rattled investors. Additionally, the company posted an operating loss of $60.231 million for the quarter, further fueling concerns about its financial performance.</p>\n\n<p>On a more positive note, Supernus reported quarterly sales of $192.103 million, surpassing analyst expectations of $180.523 million by 6.41%. However, this represents only a 9.34% increase from the $175.689 million reported in the same quarter last year, which may have been viewed as insufficient growth by some investors. The company also provided guidance for full-year revenue between $685-705 million and adjusted operating earnings of $125-145 million, which may have fallen short of market expectations, contributing to the stock's after-hours plunge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Supernus Pharmaceuticals Plunges 12.28% After-Hours Despite Beating Q3 Estimates, Reports Operating Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Supernus Pharmaceuticals Plunges 12.28% After-Hours Despite Beating Q3 Estimates, Reports Operating Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 05:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) tumbled 12.28% in after-hours trading on Tuesday, despite the company reporting better-than-expected third-quarter results. The sharp decline reflects investor concerns over the company's profitability and modest revenue growth.</p>\n\n<p>Supernus reported a quarterly loss of $0.80 per share, which, while beating analyst estimates of a $1.10 loss, represents a significant downturn from the $0.69 earnings per share reported in the same period last year. This 215.94% decrease in earnings appears to have rattled investors. Additionally, the company posted an operating loss of $60.231 million for the quarter, further fueling concerns about its financial performance.</p>\n\n<p>On a more positive note, Supernus reported quarterly sales of $192.103 million, surpassing analyst expectations of $180.523 million by 6.41%. However, this represents only a 9.34% increase from the $175.689 million reported in the same quarter last year, which may have been viewed as insufficient growth by some investors. The company also provided guidance for full-year revenue between $685-705 million and adjusted operating earnings of $125-145 million, which may have fallen short of market expectations, contributing to the stock's after-hours plunge.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SUPN","symbol_name":"Supernus Pharmaceuticals","start_time":0,"source_url":"","article_id":"1178412502","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178412502","pubTimestamp":1762292405,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) tumbled 12.28% in after-hours trading on Tuesday, despite the company reporting better-than-expected third-quarter results. The sharp decline reflects...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SUPN":"Supernus Pharmaceuticals"},"translate_title":"个股追踪|Supernus Pharmaceuticals盘后暴跌12.28%尽管超过Q3预期仍报告运营亏损","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SUPN":1},"content_text":"Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) tumbled 12.28% in after-hours trading on Tuesday, despite the company reporting better-than-expected third-quarter results. The sharp decline reflects investor concerns over the company's profitability and modest revenue growth.\nSupernus reported a quarterly loss of $0.80 per share, which, while beating analyst estimates of a $1.10 loss, represents a significant downturn from the $0.69 earnings per share reported in the same period last year. This 215.94% decrease in earnings appears to have rattled investors. Additionally, the company posted an operating loss of $60.231 million for the quarter, further fueling concerns about its financial performance.\nOn a more positive note, Supernus reported quarterly sales of $192.103 million, surpassing analyst expectations of $180.523 million by 6.41%. However, this represents only a 9.34% increase from the $175.689 million reported in the same quarter last year, which may have been viewed as insufficient growth by some investors. The company also provided guidance for full-year revenue between $685-705 million and adjusted operating earnings of $125-145 million, which may have fallen short of market expectations, contributing to the stock's after-hours plunge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178412502","isCrawlerRequest":true}